CING earnings: next report 2026-08-18, real EPS beat/miss history, analyst consensus Buy, P/E -0.96. Updated 2026-07-23.
Cingulate (CING) Research Hub
Cingulate (CING) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 5.02 USD (-3.65%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.96, market cap 0.03B. This hub links to the full technical, earnings and options research available for CING.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 5.02 USD (-3.65%) |
| 52-week range | 4.25 USD – 5.95 USD |
| Trend regime | Range |
| 14-day RSI | 43.7 (Bearish) |
| Trailing P/E | -0.96 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-18 |
Available research for CING
Covered Call on CING: how it works, illustrative setup around the real 5.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CING: how it works, illustrative setup around the real 5.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CING: how it works, illustrative setup around the real 5.02 USD price, max profit/loss, breakeven and when to use it. Educational.
CING technical analysis: range, last 5.02 USD, RSI 43.7, 52w range 4.25 USD–5.95 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CING in?
Cingulate (CING) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CING in an uptrend or downtrend?
As of 2026-09-11, CING is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CING's trailing P/E ratio?
CING's trailing P/E is -0.96, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does CING next report earnings?
CING is next scheduled to report earnings on 2026-08-18, with a consensus EPS estimate of -0.63 USD.